Washington, D.C. - The Prescription Drug User Fee Act of 1992 reducedthe time the U.S. Food and Drug Administration needs to review and approvenew pharmaceuticals, said the Tufts Center for the Study of Drug Development.
The Weekly Roundup: September 23-27
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
LEO Pharma Presents Extensive Data at EADV
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations
Post Hoc Analysis of Vilobelimab in Hidradenitis Suppurativa Suggests Clinically Meaningful Benefits